 NEW YORK, Aug. 12, 2021 GLOBE NEWSWIRE -- Anavex Life Sciences Corp. Anavex or the Company Nasdaq: AVXL, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimers disease, Parkinsons disease, Rett syndrome and other central nervous system CNS diseases, today reported financial results for its fiscal quarter ended June 30, 2021. 